Evidence map›Paper›PMID 39702302›Full record

ArticleJournal of ovarian research2024

Scutellaria barbata D.Don and Hedyotis diffusa Willd herb pair combined with cisplatin synergistically inhibits ovarian cancer progression through modulating oxidative stress via NRF2-FTH1 autophagic degradation pathway.

Xue Sui, Bingqing Gao, Liu Zhang, Yanmin Wang, Junnan Ma, Xingchen Wu, Chenyu Zhou, Min Liu, Lin Zhang

Abstract read
In one paragraph

Article in Journal of ovarian research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Anisodus tanguticus in Cancer Research: A Review of Traditional Use, Phytochemistry, Extraction Methods, and Preclinical Antitumor Evidence.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xue Sui *Institute (College) of Integrative Medicine, Dalian Medical University, Dalian, 116044, China.
Bingqing Gao *Institute (College) of Integrative Medicine, Dalian Medical University, Dalian, 116044, China.
Liu ZhangInstitute (College) of Integrative Medicine, Dalian Medical University, Dalian, 116044, China.
Yanmin WangInstitute (College) of Integrative Medicine, Dalian Medical University, Dalian, 116044, China.
Junnan MaInstitute (College) of Integrative Medicine, Dalian Medical University, Dalian, 116044, China.
Xingchen WuInstitute (College) of Integrative Medicine, Dalian Medical University, Dalian, 116044, China.
Chenyu ZhouInstitute (College) of Integrative Medicine, Dalian Medical University, Dalian, 116044, China.
Min LiuAdvanced Institute for Medical Sciences, Dalian Medical University, Dalian, 116044, China. 15040578452@163.com.
Lin ZhangInstitute (College) of Integrative Medicine, Dalian Medical University, Dalian, 116044, China. zhl8247@163.com.

Funding

National Natural Science Foundation of China 81873195Natural Science Foundation of Liaoning Province 2023010109-JH2/1013
6 · The paper itself

Abstract

backgroundCisplatin (DDP) is one of the most effective anticancer drugs, commonly used to treat advanced ovarian cancer (OC). However, DDP has significant limitations of platinum-based drugs, including chemical resistance and high-dose toxic side effects. Traditional Chinese medicines (TCMs) often presented in the form of formula, in which the herb pair was the basic unit. Scutellaria barbata D.Don and Hedyotis diffusa Willd (SB-HD) are famous TCMs herb pair that have been shown to help treat multiple types of cancers. However, the synergistic effects and mechanism of combination of SB-HD and DDP to enhance DDP chemosensitivity in OC are still unknown.

resultsIn vitro, we found that the optimal proportion of SB-HD to inhibit the proliferation of OC cells was 2:1, SB-HD and DDP were shown to synergistically reduce the viability of OC cells, inhibit the colony formation, promote cell cycle arrest and apoptosis, as well as inhibit cell migration and invasion. In vivo, combination treatment significantly inhibited the growth of subcutaneous tumors in BALB/c nude mice and reduced the toxic side effects of DDP. Mechanistically, SB-HD and DDP combination treatment significantly promoted oxidative stress response, decreased MMP, inhibited ATP production, decreased ROS levels and increased SOD activity, increased the expression of NRF2, HO-1, ATG5 and LC3, decreased the expression of p62 and FTH1 both in OC cells and tumor tissue of mice. Inhibitor 3-MA (Methyladenine, autophagy inhibitor) and Fer-1 (Ferrostatin-1, iron ion inhibitor) can effectively reverse the expression changes of the key target proteins, but not ZnPP (Zinc protoporphyrin, HO-1 inhibitor). Through bioinformatics analysis, it was found that the abnormal expression level of NRF2 and FTH1 mRNA has a high prognostic value, at the same time, the other four key proteins respectively or interacting with NRF2 and FTH1, also play important roles in the occurrence and development of OC.

conclusionOur findings uncover a synergistic effect of SB-HD and DDP against OC through modulating oxidative stress via NRF2-FTH1 autophagic degradation pathway, which may provide an important theoretical foundation for the use of SB-HD and a new strategy for enhancing DDP chemosensitivity as well as reducing toxic side effects.

Indexed as

AutophagyCisplatinHedyotisNF-E2-Related Factor 2Ovarian NeoplasmsOxidative StressScutellariaAnimalsCell Line, TumorDrugs, Chinese HerbalDrug SynergismFemaleHumansMiceMice, NudePlant ExtractsCisplatinDrugs, Chinese HerbalNFE2L2 protein, humanNF-E2-Related Factor 2Plant ExtractsScutellaria barbata extractDDP chemosensitivityFerritin autophagic degradationNRF2/HO-1Ovarian cancerOxidative stressScutellaria barbata D.Don and Hedyotis diffusa Willd

Identifiers

PMID39702302
PMCPMC11658162

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.